Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
Live Oak Bancshares Q2 2026 Earnings Call - Revenue Outpaces Costs as Checking and AI Initiatives Scale
Live Oak Bancshares delivered another quarter of compounding earnings power, with adjusted EPS rising 20% to $0.77 as core revenue expanded 11% while expenses contracted 1%. The bank’s operating lever...
- Adjusted EPS reached $0.77, up 20% year-over-year, driven by revenue growing 11% while total expenses contracted 1%.
- Loan production hit $1.5 billion across 33 industries, pushing the total loan book to $13 billion with a record $4.6 billion pipeline.
- Live Oak Express posted record $82 million in originations and $5 million in gains on sale, targeting a $750 million annual run rate.
- +7 more takeaways
Brandywine Realty Trust Q2 2026 Earnings Call - Raised $305M Sales Target; Philadelphia Leasing Outpaces Market Amid Austin Drag
Brandywine Realty Trust reported Q2 FFO of $0.13 per share, missing consensus by a penny but beating prior management guidance, while holding a full-year midpoint of $0.55. The dominant theme is capit...
- Q2 FFO came in at $0.13 per share. This misses consensus by a penny but beats the guidance management provided on the Q1 call. The full-year midpoint remains $0.55, with the range narrowed to reflect better-than-expected tenant retention and leasing activity.
- Management raised the asset sale target to $305 million, up $15 million from the original business plan. $208 million is already complete, and the remainder is under agreement with hard money deposits scheduled to close in Q3. Pricing across all sales is in line with original guidance.
- Leasing momentum is turning a corner. The company reported 88,000 square feet of positive net absorption in Q2. The operating portfolio pipeline grew 13% quarter-over-quarter to nearly 2 million square feet, with 456,000 square feet in advanced stages of negotiation. Management expects positive full-year net absorption for the first time in several years.
- +9 more takeaways
"Medpace" Q2 2026 Earnings Call - Backlog Conversion Runs Hot as Oncology Reclaims Mix and Cancellations Cool
Medpace delivered a quarter defined by operational tightening and a quiet structural shift. Revenue climbed 17.2 percent to $707.3 million, while net income surged 34.5 percent to $121.4 million, prov...
- Revenue and earnings are running hot. Q2 revenue hit $707.3 million, up 17.2 percent year over year, while net income surged 34.5 percent to $121.4 million, powered by operating leverage and a compressed effective tax rate.
- Backlog conversion is outpacing history. The burn rate climbed to 24.1 percent against a long term baseline near 18 percent. Management explicitly rejects the metabolic mix theory, pointing instead to stricter backlog gating and tighter interim analysis checkpoints.
- Oncology is reclaiming the throne. Therapeutic mix is shifting back to historical norms, with oncology now driving over half of new awards and bookings. The metabolic supercycle that concentrated revenue among the top five clients is cooling.
- +7 more takeaways
"Colony Bankcorp" Q2 2024 Earnings Call - Hits 1.20% Operating ROA While Prioritizing Pricing Discipline Over Volume
Colony Bankcorp finally cracked the code on its profitability mandate, delivering a 1.20% operating return on assets for the first time. The result came from a deliberate pivot: management chose prici...
- Colony Bankcorp finally hit its 1.20% operating ROA target, proving that disciplined pricing beats volume chasing in a volatile rate environment.
- Net interest margin expanded to 3.52%, driven by a six basis point jump in earning asset yields while funding costs held steady at 1.95%.
- Management chose pricing over pace. New and renewed loan rates stayed in the low sevens, pushing annualized growth to 8.5% but signaling near-term volume could slip below the 8% threshold.
- +7 more takeaways
"argenx" Q2 2026 Earnings Call - VYVGART Sales Hit $1.5B as Seronegative Expansion and Pipeline Catalysts Accelerate
argenx delivered another quarter of compounding execution, pushing VYVGART product net sales to $1.5 billion and securing its 18th consecutive quarter of growth. The commercial engine is clearly firin...
- Q2 2026 product net sales reached $1.5 billion, marking 60% year-over-year growth and the company’s 18th straight quarter of revenue expansion.
- U.S. commercial momentum is accelerating, with the prefilled syringe driving 80% new patient uptake in the quarter and expanding the prescriber base beyond 5,000 neurologists.
- The seronegative gMG label expansion added roughly 11,000 patients to the addressable market, with payers covering 55% of U.S. commercial lives in just ten weeks and largely eliminating mandatory serology testing.
- +7 more takeaways
"Rollins, Inc." Q2 2026 Earnings Call - Residential Demand Slowdown Triggers Revised Full-Year Guidance and Leadership Overhaul
Rollins delivered a solid topline but stumbled on execution where the market pays attention. Q2 revenue climbed 7.9 percent, yet organic growth of just 5.7 percent missed management targets. The weakn...
- Q2 revenue grew 7.9 percent year-over-year, but organic growth of 5.7 percent fell short of internal targets, driven by a concentrated slowdown in consumer-initiated residential demand.
- The weakness was highly channel-dependent. Digital and search-heavy brands like Orkin lagged, while relationship-driven names such as HomeTeam and Fox delivered double-digit organic growth.
- Customer retention remained stable and pricing power held firm, confirming the miss was purely a top-of-funnel volume issue rather than a deterioration in the customer base.
- +9 more takeaways
Wyndham Hotels & Resorts" Q2 2026 Earnings Call - U.S. RevPAR Momentum Drives Raised Guidance and AI-Driven Margin Expansion
Wyndham Hotels & Resorts just quietly rewritten its own forecast. Management lifted full-year U.S. RevPAR from flat to a solid 2% after the second quarter outperformed by 120 basis points. The lift is...
- U.S. RevPAR grew 2% in Q2, beating management expectations by 120 basis points. The lift came from a 160 bps ADR increase and 60 bps occupancy gain, prompting a full-year U.S. RevPAR outlook revision from flat to +2%.
- Global RevPAR guidance raised to flat to +1%, up 100 basis points at the low end. Net room growth guidance remains unchanged at 4% to 4.5% excluding Revo.
- Full-year adjusted EBITDA raised to $735 million to $745 million, with net revenues projected at $1.48 billion to $1.50 billion. Comparable EBITDA growth is expected to accelerate in Q4 due to lapping Q3 2025 variable cost reductions.
- +7 more takeaways
Waste Connections Q2 2026 Earnings Call - Raised Full-Year EBITDA Guidance and Margin Expansion Despite Volume Headwinds
Waste Connections did not just meet the bar in the second quarter. It moved it. Revenue climbed 6.4 percent to $2.562 billion while adjusted EBITDA surged 6.8 percent to $840.1 million. Management imm...
- Q2 revenue reached $2.562 billion and adjusted EBITDA hit $840.1 million, both exceeding expectations and triggering a full-year outlook upgrade.
- Full-year 2026 adjusted EBITDA guidance raised to $3.33 billion to $3.34 billion, targeting 33.2 percent to 33.3 percent margins.
- Core pricing held at 5.6 percent while fuel surcharges added 1.1 percent, fully absorbing rapidly spiking diesel costs and protecting the 32.8 percent EBITDA margin.
- +7 more takeaways
Ameriprise Financial Q2 2026 Earnings Call - AI-Driven Productivity and 55% ROE Outpace Industry Recruiting Arms Race
Ameriprise Financial delivered another quarter of disciplined execution, posting 13% revenue growth and a best-in-class 55% return on equity. The firm is treating technology as a profit multiplier rat...
- Q2 revenue surged 13% to $4.9 billion, while adjusted operating earnings climbed 14% to $1 billion, driven by asset growth and transactional activity.
- Return on equity reached a best-in-class 55%, up from 51.5% a year ago, underscoring durable operating leverage across the platform.
- Wrap assets hit a record $732 billion, up 19%, as market appreciation and advisor productivity gains compounded fee-based revenue.
- +7 more takeaways
"Horizon Bancorp" Q2 2026 Earnings Call - Margin Expansion and Disciplined Commercial Growth Drive Capital Accretion
Horizon Bancorp delivered a quarter defined by disciplined execution rather than market theater. Net interest margin expanded eight basis points to 4.37%, fueled by loan yield gains that outpaced the ...
- Net interest margin expanded eight basis points to 4.37% in Q2, driven by loan yield gains outpacing deposit cost increases.
- Management guides H2 2026 margin to 4.30% to 4.35%, attributing the slight percentage pullback to elevated cash balances rather than earnings compression.
- Commercial lending led growth, with C&I balances adding $62 million to represent 31% of the commercial portfolio.
- +7 more takeaways